Australia markets close in 2 hours

Eloxx Pharmaceuticals, Inc. (ELOX)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
5.02+0.16 (+3.29%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.86
Bid4.90 x 2900
Ask5.23 x 1200
Day's range4.86 - 5.24
52-week range1.70 - 10.90
Avg. volume998,900
Market cap15.353M
Beta (5Y monthly)2.67
PE ratio (TTM)N/A
EPS (TTM)-9.85
Earnings date08 Nov 2023 - 13 Nov 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est60.00
  • GlobeNewswire

    Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

    WATERTOWN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 380,590 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $5.255 per share (or common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market

  • GlobeNewswire

    Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

    Highly regarded renal pathologist and transmission electron microscopy (TEM) expert independently confirms previously reported qualitative assessment by Mayo Clinic of TEM biopsy scans All three patients treated with ELX-02 showed a visual improvement in podocyte foot process effacement post-treatment in kidney biopsies demonstrating the disease modifying effect of ELX-02 Podocyte foot process effacement is a hallmark of Alport syndrome Eloxx intends to gain alignment with U.S. Food and Drug Adm

  • GlobeNewswire

    Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013

    Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport syndrome with nonsense mutations Rebound in average UPCR 3-months post treatment provides further evidence that proteinuria remission in one out of three patients was drug related All 3 Alport patients (100% response rate) treated with ELX-02 had biopsy confirmed disease regression, suggesting clinical benefit likely with longer treatment duration Significant str